CRISPR Therapeutics reports CASGEVY Q3 revenue of $99M, up 30% from prior quarter

CRISPR Therapeutics says CASGEVY Q3 revenue was $99M, up 30% from the prior quarter, with more than 750 patients having initiated treatment.

Detected & updated continuously · Source: Nebula